Image

Indonesia, Malaysia, Philippines, Thailand and Vietnam IgA Nephropathy Market – Industry Trends and Forecast to 2034

Pharmaceutical

Image

Indonesia, Malaysia, Philippines, Thailand and Vietnam IgA Nephropathy Market – Industry Trends and Forecast to 2034

  • Pharmaceutical
  • Published Report
  • Jan 2024
  • Country Level
  • 350 Pages
  • No of Tables: 127
  • No of Figures: 37

Indonesia, Malaysia, Philippines, Thailand and Vietnam IgA Nephropathy Market – Industry Trends and Forecast to 2034

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2023–2034
Diagram Market Size (Base Year) USD 15,716.44 USD million
Diagram Market Size (Forecast Year) USD 42,340.41 USD million
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA Nephropathy Market, By Disease Type (Primary IgA Nephropathy and Secondary IgA Nephropathy), Type (Diagnosis and Treatment), Population Type (Adults, Geriatric, and Pediatric), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Diagnostic Centers, Ambulatory Care Centers, Home Healthcare, and Others), Distribution Channel (Retail Sales, Direct Tenders, and Others) - Industry Trends and Forecast to 2034.

Indonesia, Malaysia, Philippines, Thailand and Vietnam Iga Nephropathy Market Analysis and Size

IgA nephropathy, also known as Berger's disease, is a kidney disease that occurs when IgA concentration increases in the kidneys, causing inflammation that damages the kidney tissues. IgA is an antibody-a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. It is an orphan disease designated as an orphan indication. This disorder is highly prevalent in countries such as Vietnam and Thailand among others.

Indonesia, Malaysia, Philippines, Thailand and Vietnam Iga Nephropathy MarketIndonesia, Malaysia, Philippines, Thailand and Vietnam Iga Nephropathy Market

The rise in IgA nephropathy cases propels market growth as it necessitates an increased focus on R&D and investment in therapeutic solutions. A growing patient population underscores the demand for effective treatments, prompting pharmaceutical companies to innovate and introduce new drug candidates. The expanding market for IgA nephropathy not only attracts heightened R&D expenditure but also stimulates competition among industry players.

Data Bridge Market Research analyzes that the Indonesia, Malaysia, Thailand, Philippines, and Vietnam IgA nephropathy market is expected to reach USD 42,340.41 thousand by 2034 from USD 15,716.44 thousand in 2023, growing with a CAGR of 10.1% in the forecast period of 2024 to 2034.

Report Metric

Details

Forecast Period

2024 to 2034

Base Year

2023

Historic Years

2022 (Customizable to 2016–2021)

Quantitative Units

Revenue in USD Thousand

Segments Covered

Disease Type (Primary IgA Nephropathy and Secondary IgA Nephropathy), Type (Diagnosis and Treatment), Population Type (Adults, Geriatric, and Pediatric), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Diagnostic Centers, Ambulatory Care Centers, Home Healthcare, and Others), Distribution Channel (Retail Sales, Direct Tenders, and Others)  

Countries Covered

Indonesia, Malaysia, Philippines, Thailand, and Vietnam

Market Players Covered

Sun Pharmaceutical Industries Ltd, Pfizer Inc., Zydus Group, Novartis AG, ARKRAY USA, Inc., and Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.) among others

Market Definition

IgA nephropathy, also known as Berger's disease, is a kidney disease caused by the build-up of IgA deposits in kidneys, which cause inflammation and damage to the kidney tissues. Antibodies such as IgA are proteins produced by the immune system to shield the body from foreign substances, including bacteria and viruses. The complication of this disease is the End Stage Kidney Disease (ESKD), which needs dialysis for treatment. The current treatment is used for preventing the progression of the disease, and the treatment of IgA nephropathy is lengthy, which provides sustainable market growth. Diagnosing this disease is also a challenging task as various urine analyzers, blood tests, and kidney biopsies are performed for the detection. The population is seen to have a high prevalence of IgA nephropathy during the epidemiology studies. In the forecast period, most of the targeted therapies are expected to be approved, which is supposed to increase the market size.

Indonesia, Malaysia, Philippines, Thailand and Vietnam IgA Nephropathy Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:

Drivers

  • Rise in the Number of IgA Nephropathy Cases

IgA nephropathy, also known as Berger's disease, is a kidney disease that occurs when IgA concentration increases in the kidneys, causing inflammation that damages the kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. It is an orphan disease designated as an orphan indication.

  • Increase in the Availability of IgA-Targeted Pipeline Drugs

IgA nephropathy is a disorder that needs to be investigated thoroughly to get a novel and more targeted treatment option. Many pipeline products are currently being developed which are in different phases of clinical trials or under the approval process from regulatory bodies.

The number of pipeline drugs is increasing for IgA nephropathy and some of the potential drug candidates are in the final stage and are going to enter the market in the forecast period, thereby increasing the market size. Thus, an increase in the availability of IgA-targeted pipeline drugs is driving market growth.

Indonesia, Malaysia, Philippines, Thailand and Vietnam Iga Nephropathy Market

Opportunity

  • Collaboration among Market Players for Drug Development

The IgA nephropathy market has great potential and can attain lucrative growth in the forecast period. However, the market players and new entrants need to strategically study the opportunities generated by the market to attain a stronghold in the market.

One of the most strategic ways to hold and use the opportunities in the market is the global collaboration to expand the business. Many new entrants in the market and the existing market players collaborate to bring new advanced products to the market.

Restraint/Challenge

  • High Cost of IgA Nephropathy Treatment

IgA nephropathy treatment comprises diagnosis and further treatment with a wide range of drugs, including blood pressure-lowering agents, immunosuppressive agents, cholesterol-lowering drugs, and various supplements. The disease diagnosis includes various blood tests, urinalysis, some radioactive tests, and kidney biopsy.

The total cost of treatment or the cumulative expense of diagnosis and treatment is relatively high. The instance given below describes the cost per pocket if reimbursement is not provided, which is a major drawback in emerging countries.

Recent Developments

  • In December 2023, Novartis AG performed an investigational iptacopan Phase III study that demonstrated clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G). This development helped the company boost its revenue growth
  • In October 2023, Novartis AG’s Phase III clinical study demonstrated a significant proteinuria reduction in patients suffering from IgA nephropathy. The phase III ALIGN study met its primary endpoint, demonstrating the superiority of atrasentan vs. placebo in proteinuria reduction at 36-week interim analysis.  IgAN is a progressive kidney disease affecting mostly young adults, and is a major cause of chronic kidney disease and kidney failure worldwide. This development helped the company boost the market growth.

Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA Nephropathy Market Scope

The Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA nephropathy market is segmented into six notable segments based on disease type, type, population type, route of administration, end user, and distribution channel.

Disease Type

  • Primary IgA Nephropathy
  • Secondary IgA Nephropathy

On the basis of disease type, the market is segmented into primary IgA nephropathy and secondary IgA nephropathy.

Type

  • Diagnosis
  • Treatment

On the basis of type, the market is segmented into diagnosis and treatment.  

Population Type

  • Adults
  • Geriatric
  • Pediatric

On the basis of population type, the market is segmented into adults, geriatric, and pediatric.

Route of Administration

  • Oral
  • Parenteral
  • Others

On the basis of route of administration, the market is segmented into oral, parenteral, and others.

End User

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Ambulatory Care Centers
  • Home Healthcare
  • Others

On the basis of end user, the market is segmented into hospitals, speciality clinics, diagnostic centers, ambulatory care centers, home healthcare, and others.

Distribution Channel

  • Retail Sales
  • Direct Tenders
  • Others

On the basis of distribution channel, the market is segmented into retail sales, direct tenders, and others.

Indonesia, Malaysia, Philippines, Thailand and Vietnam Iga Nephropathy Market

Competitive Landscape and Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA Nephropathy Market Share Analysis

The Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA nephropathy market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, country presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA nephropathy market.

Some of the major market players operating in the Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA nephropathy market are Sun Pharmaceutical Industries Ltd, Pfizer Inc., Zydus Group, Novartis AG, ARKRAY USA, Inc., and Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.) and among others.  


SKU-

TABLE 1 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2022-2034 (USD THOUSAND)

TABLE 2 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 3 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 4 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 5 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 6 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 7 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 8 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 9 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 10 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 11 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 12 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM BLOOD CHOLESTEROL LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 13 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 14 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2022-2034 (USD THOUSAND)

TABLE 15 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 16 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM ORAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 17 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 18 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY END USER, 2022-2034 (USD THOUSAND)

TABLE 19 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM HOSPITALS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 20 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2022-2034 (USD THOUSAND)

TABLE 21 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM RETAIL SALES IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 22 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY REGION, 2022-2034 (USD THOUSAND)

TABLE 23 MALAYSIA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2022-2034 (USD THOUSAND)

TABLE 24 MALAYSIA IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 25 MALAYSIA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 26 MALAYSIA URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 27 MALAYSIA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 28 MALAYSIA BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 29 MALAYSIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 30 MALAYSIA ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 31 MALAYSIA IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 32 MALAYSIA CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 33 MALAYSIA DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 34 MALAYSIA BLOOD CHOLESTEROL LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 35 MALAYSIA SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 36 MALAYSIA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2022-2034 (USD THOUSAND)

TABLE 37 MALAYSIA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 38 MALAYSIA ORAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 39 MALAYSIA PARENTERAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 40 MALAYSIA IGA NEPHROPATHY MARKET, BY END USER, 2022-2034 (USD THOUSAND)

TABLE 41 MALAYSIA HOSPITALS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 42 MALAYSIA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2022-2034 (USD THOUSAND)

TABLE 43 MALAYSIA RETAIL SALES IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 44 THAILAND IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2022-2034 (USD THOUSAND)

TABLE 45 THAILAND IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 46 THAILAND DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 47 THAILAND URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 48 THAILAND TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 49 THAILAND BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 50 THAILAND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 51 THAILAND ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 52 THAILAND IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 53 THAILAND CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 54 THAILAND DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 55 THAILAND BLOOD CHOLESTEROL LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 56 THAILAND SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 57 THAILAND IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2022-2034 (USD THOUSAND)

TABLE 58 THAILAND IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 59 THAILAND ORAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 60 THAILAND PARENTERAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 61 THAILAND IGA NEPHROPATHY MARKET, BY END USER, 2022-2034 (USD THOUSAND)

TABLE 62 THAILAND HOSPITALS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 63 THAILAND IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2022-2034 (USD THOUSAND)

TABLE 64 THAILAND RETAIL SALES IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 65 INDONESIA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2022-2034 (USD THOUSAND)

TABLE 66 INDONESIA IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 67 INDONESIA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 68 INDONESIA URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 69 INDONESIA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 70 INDONESIA BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 71 INDONESIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 72 INDONESIA ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 73 INDONESIA IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 74 INDONESIA CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 75 INDONESIA DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 76 INDONESIA BLOOD CHOLESTEROL LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 77 INDONESIA SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 78 INDONESIA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2022-2034 (USD THOUSAND)

TABLE 79 INDONESIA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 80 INDONESIA ORAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 81 INDONESIA PARENTERAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 82 INDONESIA IGA NEPHROPATHY MARKET, BY END USER, 2022-2034 (USD THOUSAND)

TABLE 83 INDONESIA HOSPITALS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 84 INDONESIA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2022-2034 (USD THOUSAND)

TABLE 85 INDONESIA RETAIL SALES IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 86 PHILIPPINES IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2022-2034 (USD THOUSAND)

TABLE 87 PHILIPPINES IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 88 PHILIPPINES DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 89 PHILIPPINES URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 90 PHILIPPINES TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 91 PHILIPPINES BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 92 PHILIPPINES ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 93 PHILIPPINES ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 94 PHILIPPINES IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 95 PHILIPPINES CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 96 PHILIPPINES DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 97 PHILIPPINES BLOOD CHOLESTEROL LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 98 PHILIPPINES SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 99 PHILIPPINES IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2022-2034 (USD THOUSAND)

TABLE 100 PHILIPPINES IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 101 PHILIPPINES ORAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 102 PHILIPPINES PARENTERAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 103 PHILIPPINES IGA NEPHROPATHY MARKET, BY END USER, 2022-2034 (USD THOUSAND)

TABLE 104 PHILIPPINES HOSPITALS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 105 PHILIPPINES IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2022-2034 (USD THOUSAND)

TABLE 106 PHILIPPINES RETAIL SALES IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 107 VIETNAM IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2022-2034 (USD THOUSAND)

TABLE 108 VIETNAM IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 109 VIETNAM DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 110 VIETNAM URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 111 VIETNAM TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 112 VIETNAM BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 113 VIETNAM ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 114 VIETNAM ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 115 VIETNAM IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 116 VIETNAM CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 117 VIETNAM DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 118 VIETNAM BLOOD CHOLESTEROL LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 119 VIETNAM SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 120 VIETNAM IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2022-2034 (USD THOUSAND)

TABLE 121 VIETNAM IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 122 VIETNAM ORAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 123 VIETNAM PARENTERAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND)

TABLE 124 VIETNAM IGA NEPHROPATHY MARKET, BY END USER, 2022-2034 (USD THOUSAND)

TABLE 125 VIETNAM HOSPITALS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

TABLE 126 VIETNAM IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2022-2034 (USD THOUSAND)

TABLE 127 VIETNAM RETAIL SALES IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Indonesia, Malaysia, Thailand, Philippines, and Vietnam IgA nephropathy market size will be worth USD 42,340.41 thousand by 2034.
The growth rate of the Indonesia, Malaysia, Thailand, Philippines, and Vietnam IgA nephropathy market is 10.1% by 2034.
Rise in IgA nephropathy cases & availability of IgA-targeted pipeline drugs are the growth drivers of the Indonesia, Malaysia, Thailand, Philippines, and Vietnam IgA nephropathy market.
Disease type, type, population type, route of administration, end user, and distribution channel are the factors on which the Indonesia, Malaysia, Thailand, Philippines, and Vietnam IgA nephropathy market research is based.
Major companies in the Indonesia, Malaysia, Thailand, Philippines, and Vietnam IgA nephropathy market are Sun Pharmaceutical Industries Ltd, Pfizer Inc., Zydus Group, Novartis AG, ARKRAY USA, Inc., and Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.) among others.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials